Применение циклоспорина при синдроме «сухого глаза»

Обложка

Цитировать

Полный текст

Аннотация

Данный обзор литературы посвящён необходимости проведения противовоспалительной терапии при синдроме «сухого глаза». Представлены причины развития и механизмы патогенеза синдрома «сухого глаза». Описаны принципы действия различных групп противовоспалительных препаратов. Освещены результаты исследований эффективности и перечислены принципы назначения циклоспорина при синдроме «сухого глаза».

Об авторах

Инна Александровна Рикс

ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова» Минздрава России

Автор, ответственный за переписку.
Email: riks0503@yandex.ru
SPIN-код: 4297-6543

канд. мед. наук, ассистент кафедры офтальмологии с клиникой

Россия, 197022, г. Санкт-Петербург, ул. Льва Толстого, 6-8

Список литературы

  1. Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802-812. https://doi.org/10.1016/j.jtos.2017.08.003.
  2. DEWS Epidemiology. The epidemiology of dry eye disease: report of the epidemiology subcommittee of the international dry eye workshop (2007). Ocul Surf. 2007;5(2):93-107. https://doi.org/10.1016/S1542-0124(12)70082-4.
  3. Lin PY, Tsai SY, Cheng CY, et al. Prevalence of dry eye among an elderly Chinese population in Taiwan: the shihpai eye study. Ophthalmology. 2003;110(6):1096-1101. https://doi.org/10.1016/S0161-6420(03)00262-8.
  4. McCarty CA, Bansal AK, Livingston PM, et al. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998;105(6):1114-9. https://doi.org/10.1016/S0161-6420(98)96016-X.
  5. DEWS Epidemiology. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop (2007). Ocul Surf. 2007;5(2):75-92. https://doi.org/10.1016/s1542-0124(12)70081-2.
  6. Davis EA, Dohlman CH. Neurotrophic keratitis. Int Ophthalmol Clin. 2001;41(1):1-11. https://doi.org/10.1097/00004397-200101000-00003.
  7. Bonini S, Rama P, Olzi D, Lambiase A. Neurotrophic keratitis. Eye (Lond). 2003;17(8):989-995. https://doi.org/10.1038/sj.eye.6700616.
  8. Benítez del Castillo JM, Wasfy MA, Fernandez C, Garcia-Sanchez J. An in vivo confocal masked study on corneal epithelium and subbasal nerves in patients with dry eye. Invest Ophthalmol Vis Sci. 2004;45(9):3030-3035. https://doi.org/10.1167/iovs.04-0251.
  9. Creuzot-Garcher C. La sécheresse oculaire liée aux médications systémiques. J Fr Ophtalmol. 2009;32(1):64-70. https://doi.org/10.1016/j.jfo.2008.11.001.
  10. Apostol S, Filip M, Dragne C, Filip A. Dry eye syndrome. Etiological and therapeutic aspects. Oftalmologia. 2003;59(4):28-31.
  11. Kam WR, Sullivan DA. Neurotransmitter influence on human meibomian gland epithelial cells. Invest Ophthalmol Vis Sci. 2011;52(12):8543-8548. https://doi.org/10.1167/iovs.11-8113.
  12. Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1 % cyclosporine a cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287-296. https://doi.org/10.5301/ejo.5000779.
  13. Goto E, Tseng SC. Differentiation of lipid tear deficiency dry eye by kinetic analysis of tear interference images. Arch Ophthalmol. 2003;121(2):173-180. https://doi.org/10.1001/archopht.121.2.173.
  14. Сафонова Т.Н., Овчинникова А.А., Федоров А.А., Полунин Г.С. Сухой кератоконъюнктивит при синдроме Шегрена: диагностическое значение изменения относительного белкового состава слезы // Вестник офтальмологии. – 1998. – Т. 114. – № 2. – C. 40–42. [Safonova TN, Ovchinnikova AA, Fedorov AA, Polunin GS. Suhoy keratokonyunktivit pri sindrome Shegrena: diagnosticheskoe znachenie izmeneniya otnositel’nogo belkovogo sostava slezy. Annals of ophthalmology. 1998;114(2):40-42. (In Russ.)]
  15. Бржеский В.В., Попов В.Ю., Калинина И.В., и др. Эффективность 0,01 % раствора дексаметазона в комплексной терапии больных с синдромом «сухого глаза» // Офтальмологические ведомости. – 2016. – Т. 9. – № 3. – С. 32–44. [Brzheskiy VV, Popov VYu, Kalinina IV, et al. Efficacy of 0.01 % dexamethasone solution in comprehensive therapy of dry eye disease. Oftalmologicheskie vedomosti. 2016;9(3):32-44. (In Russ.)]. https://doi.org/10.17816/OV9332-44.
  16. Бржеский В.В., Егорова Г.Б., Егоров Е.А. Синдром «сухого глаза» и заболевания глазной поверхности: клиника, диагностика, лечение. – М.: ГЭОТАР-Медиа, 2016. – 464 с. [Brzheskiy VV, Egorova GB, Egorov EA. The dry eye disease and ocular surface disease: clinical features, diagnosis, treatment. Moscow: GEOTAR-Media; 2016. 464 р. (In Russ.)]
  17. Патент РФ на изобретение RU № 2559580. Бржеский В.В., Садовникова Н.Н., Прозорная Л.П., Попов В.Ю. Препарат для лечения синдрома «сухого глаза». [Patent RUS No. 2559580. Brzheskiy VV, Sadovnikova NN, Prozornay LP, Popov VYu. The medicine for treatment of dry eye disease. (In Russ.)]. Доступно по: https://findpatent.ru/patent/255/2559580.html. Ссылка активна на 13.07.2019.
  18. Lee JH, Min K, Kim SK, et al. Inflammatory cytokine and osmolarity changes in the tears of dry eye patients treated with topical 1% methylprednisolone. Yonsei Med J. 2014;55(1):203-208. https://doi.org/10.3349/ymj.2014.55.1.203.
  19. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83(3):526-535. https://doi.org/10.1016/j.exer.2006.02.004.
  20. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology. 1999;106(4):811-816. https://doi.org/10.1016/S0161-6420(99)90171-9.
  21. Knop E, Knop N. The role of eye-associated lymphoid tissue in corneal immune protection. J Anat. 2005;206(3):271-285. https://doi.org/10.1111/j.1469-7580.2005.00394.x.
  22. Knop N, Knop E. Conjunctiva-associated lymphoid tissue in the human eye. Am J Ophthalmol. 2000;130(3):385. https://doi.org/10.1016/s0002-9394(00)00700-5.
  23. Калинина Н.М., Попов В.Ю., Бржеский В.В. Роль цитокинов слёзной жидкости в развитии синдрома «сухого глаза» // Цитокины и воспаление. – 2015. – Т. 14. – № 1. – С. 5–10. [Kalinina NM, Popov VY, Brzheskiy VV. The role of lacrimal fluid cytokines in the development of dry eye disease (review). Cytokines & inflammation. 2015;14(1):5-10. (In Russ.)]
  24. Holly FJ, Lemp MA. Tear physiology and dry eyes. Surv Ophthalmol. 1977;22(2):69-87. https://doi.org/10.1016/0039-6257(77)90087-x.
  25. Sonoda S, Uchino E, Nakao K, Sakamoto T. Inflammatory cytokine of basal and reflex tears analysed by multicytokine assay. Br J Ophthalmol. 2006;90(1):120-122. https://doi.org/10.1136/bjo.2005.076737.
  26. Янченко С.В. Оптимизация диагностики и терапии возрастной формы синдрома «сухого глаза»: Автореф. дис. … д-ра мед. наук. – СПб., 2010. – 39 с. [Yanchenko SV. Optimizatsiya diagnostiki i terapii vozrastnoy formy sindroma «sukhogo glaza». [dissertation] Saint Petersburg; 2010. 39 р. (In Russ.)]. Доступно по: https://search.rsl.ru/ru/record/01004612320. Ссылка активна на 14.07.2019.
  27. Baudouin C, de la Maza MS, Amrane M, et al. One-year efficacy and safety of 0.1 % cyclosporine a cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 2017;27(6):678-685. https://doi.org/10.5301/ejo.5001002.
  28. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137(2):337-342. https://doi.org/10.1016/j.ajo.2003.10.036.
  29. Javadi MA, Feizi S. Dry eye syndrome. J Ophthalmic Vis Res. 2011;6(3):192-198.
  30. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1 % ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112(10):1790-1794. https://doi.org/10.1016/j.ophtha.2005.05.013.
  31. Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine 1 % ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea. 1993;12(4):315-323. https://doi.org/10.1097/00003226-199307000-00007.
  32. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin a phase 2 study group. Ophthalmology. 2000;107(5):967-974. https://doi.org/10.1016/s0161-6420(00)00035-x.
  33. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47(2-3):119-125. https://doi.org/10.1016/ s0162-3109(00)00192-2.
  34. Lallemand F, Daull P, Benita S, et al. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv. 2012;2012:604204. https://doi.org/10.1155/ 2012/604204.
  35. Daull P, Lallemand F, Garrigue JS. Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. J Pharm Pharmacol. 2014;66(4):531-541. https://doi.org/10.1111/jphp.12075.
  36. Daull P, Lallemand F, Philips B, et al. Distribution of cyclosporine a in ocular tissues after topical administration of cyclosporine a cationic emulsions to pigmented rabbits. Cornea. 2013;32(3): 345-54. https://doi.org/10.1097/ICO.0b013e31825e83f4.
  37. Tavares Fde P, Fernandes RS, Bernardes TF, et al. Dry eye disease. Semin Ophthalmol. 2010;25(3):84-93. https://doi.org/10.3109/08820538.2010.488568.
  38. Fujishima H, Fuseya M, Ogata M, Murat D. Efficacy of bromfenac sodium ophthalmic solution for treatment of dry eye disease. Asia Pac J Ophthalmol (Phila). 2015;4(1):9-13. https://doi.org/10.1097/APO.0000000000000032.
  39. Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology. 2001;108(5):936-944. https://doi.org/10.1016/s0161-6420(00)00538-8.
  40. Lindstrom R. The pharmacologic and pathophysiologic rationale for using NSAIDs in ocular inflammatory disease and ocular surgery. Int Ophthalmol Clin. 2006;46(4):7-11. https://doi.org/10.1097/01.iio.0000212131.98760.a9.
  41. Hersh PS, Rice BA, Baer JC, et al. Topical nonsteroidal agents and corneal wound healing. Arch Ophthalmol. 1990;108(4):577-583. https://doi.org/10.1001/archopht.1990.01070060125062.
  42. Moon I, Kang HG, Yeo A, et al. Comparison of ocular surface mucin expression after topical ophthalmic drug administration in dry eye-induced mouse model. J Ocul Pharmacol Ther. 2018;34(9): 612-620. https://doi.org/10.1089/jop.2018.0005.
  43. Moore CP, McHugh JB, Thorne JG, Phillips TE. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model. Invest Ophthalmol Vis Sci. 2001;42(3):653-659.
  44. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120(3):330-337. https://doi.org/10.1001/archopht.120.3.330.
  45. Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea. 2008;27(1):64-69. https://doi.org/10.1097/ICO.0b013e318158f6dc.
  46. Avisar R, Robinson A, Appel I, et al. Diclofenac sodium, 0.1 % (Voltaren ophtha), versus sodium chloride, 5 %, in the treatment of filamentary keratitis. Cornea. 2000;19(2):145-147. https://doi.org/10.1097/00003226-200003000-00005.
  47. Aragona P, Stilo A, Ferreri F, Mobrici M. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren’s syndrome patients. Eye (Lond). 2005;19(5):535-539. https://doi.org/10.1038/sj.eye.6701537.
  48. Li Y, Johnson N, Capano M, et al. Cyclophilin-D promotes the mitochondrial permeability transition but has opposite effects on apoptosis and necrosis. Biochem J. 2004;383(Pt 1):101-109. https://doi.org/10.1042/BJ20040669.
  49. Agarwal P, Rupenthal ID. Modern approaches to the ocular delivery of cyclosporine A. Drug Discov Today. 2016;21(6):977-988. https://doi.org/10.1016/j.drudis.2016.04.002.
  50. Mandal A, Gote V, Pal D, et al. Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa) for dry eye disease. Pharm Res. 2019;36(2):36. https://doi.org/10.1007/s11095-018-2556-5.
  51. Hoy SM. Ciclosporin ophthalmic emulsion 0.1 %: a review in severe dry eye disease. Drugs. 2017;77(17):1909-1916. https://doi.org/10.1007/s40265-017-0834-x.
  52. de Oliveira RC, Wilson SE. Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease. Clin Ophthalmol. 2019;13:1115-1122. https://doi.org/10.2147/OPTH.S184412.
  53. Luchs J. Phase 3 clinical results of cyclosporine 0.09 % in a new nanomicellar ophthalmic solution to treatment keratoconjunctivitis sicca. In: American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting Washington, DC; 2018.
  54. Tauber J, Schechter BA, Bacharach J, et al. A phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. Clin Ophthalmol. 2018;12:1921-1929. https://doi.org/10.2147/OPTH.S175065.
  55. Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126(8):1046-50. https://doi.org/10.1001/archopht.126.8.1046.
  56. Chun YH, Beak JU, Kim HS, Na KS. Topical cyclosporine pretreatment of ocular surface in allogeneic hematopoietic stem cell transplant recipients. J Ocul Pharmacol Ther. 2018;34(9):628-632. https://doi.org/10.1089/jop.2018.0006.
  57. Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05 % in the treatment of severe dry eye refractory to twice-daily regimen. Cornea. 2009;28(10):1091-1096. https://doi.org/10.1097/ICO.0b013e3181a16472.
  58. Gire AI, Karakus S, Ingrodi SM, Akpek EK. Frequent dosing of topical cyclosporine a for severe ocular surface disease. J Ocul Pharmacol Ther. 2016;32(3):150-154. https://doi.org/10.1089/jop.2015.0078.
  59. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998;17(6):584-589. https://doi.org/10.1097/00003226-199811000-00002.
  60. Бржеский В.В., Сомов Е.Е. Роговично-конъюнктивальный ксероз (диагностика, клиника, лечение). – 2-е изд., частично перераб. и доп. – СПб.: Левша. Санкт-Петербург, 2003. – 120 с. [Brzheskiy VV, Somov E.E. Rogovichno-kon’’yunktival’niy kseroz (diagnostika, klinika, lechenie). 2nd ed, revised and updated. Saint Petersburg: Levsha. Saint Petersburg; 2003. 120 p. (In Russ.)]
  61. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5 %, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138(3):444-457. https://doi.org/10.1016/j.ajo.2004.04.052.
  62. Труфанов С.В., Суббот А.М., Маложен С.А., Крахмалева Д.А. Гипотеза иммунной привилегии роговицы и патофизиология отторжения кератотрансплантата // Вестник офтальмологии. – 2016. – Т. 132. – № 5. – С. 117–124. [Trufanov SV, Subbot AM, Malozhen SA, Krakhmaleva DA. Hypothesis of immune privilege of the cornea and pathophysiology of graft rejection. Annals of ophthalmology. 2016;132(5):117-124. (In Russ.)]. https://doi.org/10.17116/oftalma20161325117-124.
  63. Труфанов С.В., Суббот А.М., Маложен С.А., и др. Факторы риска, клинические проявления, методы профилактики и лечения реакции отторжения трансплантата роговицы // Вестник офтальмологии. – 2016. – Т. 132. – № 6. – С. 108–116. [Trufanov SV, Subbot AM, Malozhen SA, et al. Risk factors, clinical presentations, prevention, and treatment of corneal graft rejection. Annals of ophthalmology. 2016;132(6):108-116. (In Russ.)]. https://doi.org/10.17116/oftalma20161326108-116.

© Рикс И.А., 2019

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах